
Myovant Sciences nets $202mm in IPO on NYSE
Executive Summary
Just four months after its inception, start-up Myovant Sciences Ltd. (men’s and women’s health therapeutics) netted $202mm in an initial public offering of 14.5mm shares at $15, the high end of its anticipated range, and up-sized from its original 13mm shares. This marks the largest biotech IPO so far this year.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com